Indivior Pharmaceuticals, Inc 6-K, filed Jan 25, 2024
Indivior Pharmaceuticals, Inc. (INDV)
6-K
2024-01-25
For: 2024-01-25
View Original
Added on
April 10, 2026
About this 6-K
Indivior Pharmaceuticals, Inc filed this 6-K on January 25, 2024.
|
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
________________________
Washington, D.C. 20549
_____________________
FORM 6-K
_____________________
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
Date: January 25, 2024
Commission File Number: 001-37835
________________________________________
Indivior PLC
________________________________________
10710 Midlothian Turnpike, Suite 125
North Chesterfield, Virginia 23235
(Address of principal executive office)
_______________________________
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ☐
|
|
EXHIBIT INDEX
|
Exhibit No.
|
Description of Exhibit
|
|
99.1
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
Indivior PLC
|
|
Date: January 25,
2024
|
/s/
Kathryn Hudson
|
|
|
Name:
Kathryn Hudson
|
|
|
Title:
Company Secretary
|
Exhibit
99.1
INDIVIOR PLC (THE 'COMPANY') - DIRECTOR/PDMR SHAREHOLDINGS -
CORRECTION
The following
amendment has been made to the 'Director/PDMR Shareholding'
announcement released on March 8, 2023
at 09:42 under
RNS number: 3033S.
In relation to the shares acquired by Mark Stejbach on March 6,
2023, the number of shares purchased was incorrectly stated due to
administrative error and has been corrected from 1,400 to
1,300.
As at the date of this announcement, Mark Stejbach has an interest
in 12,584 shares in the Company.
All other details remain unchanged.
The full amended text is shown below.
INDIVIOR PLC (THE 'COMPANY')
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS
DISCHARGING MANAGERIAL RESPONSIBILITIES ('PDMR') AND PERSONS
CLOSELY ASSOCIATED WITH THEM
The Company announces that it received notification on March 7,
2023 that Mark Stejbach, a
Non-Executive Director of the Company, acquired 1,300 shares
at an average price of £15.0229 per share on March 6,
2023.
Following this transaction, Mark Stejbach has an interest in 9,584
shares in the Company.
|
1
|
Details of the person discharging managerial responsibilities /
person closely associated
|
||
|
a)
|
Name
|
Mark Stejbach
|
|
|
2
|
Reason for the notification
|
||
|
a)
|
Position/status
|
Non-Executive Director
|
|
|
b)
|
Initial notification /Amendment
|
Amendment
|
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
Indivior PLC
|
|
|
b)
|
LEI
|
213800V3NCQTY7IED471
|
|
|
4
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted
|
||
|
a)
|
Description of the financial instrument, type of
instrument
Identification code
|
Ordinary Shares of US$0.50
ISIN: GB00BN4HT335
|
|
|
b)
|
Nature of the transaction
|
Purchase of shares
|
|
|
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
|
|
GBP
£15.0229
|
1,300
|
||
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
N/A
|
|
|
e)
|
Date of the transaction
|
March 6, 2023
|
|
|
f)
|
Place of the transaction
|
London Stock Exchange (XLON)
|
|